LearnGlossaryMarketStocksSuperinvestorsSign in

ATRA

Atara Biotherapeutics, Inc.

Healthcare · $73M market cap

Verdict

We can't put a fair value on ATRA right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-23.9% a year✗
Sales growth49.1% a year✓
Free cash flow growth—?
Return on invested capital-81.4%✗

Follow ATRA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: 1 open-market purchase worth $1,000K. Why purchases matter

Purchases

Cherry Brian N

director · 2026-09-04

Bought

$1,000K

About Atara Biotherapeutics, Inc.

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works